Italia markets closed

Grifols, S.A. (GRF.MC)

MCE - MCE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
18,64+0,60 (+3,33%)
Alla chiusura: 05:35PM CEST

Grifols, S.A.

Avinguda de la Generalitat, 152
Parc empresarial Can Sant Joan Sant Cugat del VallEs
Barcelona 08174
Spain
34 93 571 02 21
https://www.grifols.com

Settore/iHealthcare
SettoreDrug Manufacturers—General
Impiegati a tempo pieno23.245

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Raimon Grifols RouraCo-CEO & Exec. Director895kN/D1964
Mr. Víctor Grifols DeuCo-CEO & Exec. Director895kN/D1977
Mr. Alfredo Arroyo GuerraCFO & VPN/DN/D1958
Mrs. Eva Bastida TubauCorp. VP and Director of Scientific & Medical AffairsN/DN/DN/D
Ms. Nuria Pascual LapeñaVP of Corp. Treasury, Risk Management Investor Relation & Sustainability OfficerN/DN/D1964
Mr. David Ian BellGen. Counsel & Chief Corp. Devel. OfficerN/DN/D1955
Ms. Maria Teresa-Rioné LlanoChief Communications OfficerN/DN/D1965
Mr. Mateo Florencio Borrás HumbertCorp. VP & Chief HR OfficerN/DN/D1956
Ms. Montserrat Gaja LlamasChief HR OfficerN/DN/D1965
Mr. Francisco Javier Jorba RibesCorp. VP and Pres of the Biological Industrial GroupN/DN/D1951
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Governance aziendale

L'ISS Governance QualityScore di Grifols, S.A. al 1 luglio 2022 è 4. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 5; diritti degli azionisti: 6; retribuzione: 4.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.